Safe thresholds for hybrid capture 2 test in primary cervical screening
BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2941 (Published 23 May 2011) Cite this as: BMJ 2011;342:d2941- Peter Sasieni, professor of biostatistics and cancer epidemiology,
- Alejandra Castanon, epidemiologist
- 1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK
- p.sasieni{at}qmul.ac.uk
Substantial evidence shows that testing for human papillomavirus (HPV) DNA with hybrid capture 2 is more sensitive but less specific than cytology at detecting high grade cervical intraepithelial neoplasia.1 The sensitivity of hybrid capture 2 relative to cytology depends on the quality of the cytology, but its absolute sensitivity is uniformly high (about 96% overall and >90% in most studies).2 Its specificity depends on the level of HPV infection in the population. Typically 6-10% of women aged 30-64 will test positive⇑.
For many years studies have looked at whether increasing the threshold for positivity would make the test more useful by trading a small loss in sensitivity for a large reduction in the clinical false positive rate. In the linked systematic review (doi:10.1136/bmj.d2757), Rebolj and colleagues assess randomised controlled trials that investigated the effect of different cut-off points on the sensitivity and specificity of the hybrid capture 2 test.3 The authors suggest that the standard cut off of 1 relative light units/cut off (rlu/co) should be changed to 10 rlu/co.
Although the data show that the loss of sensitivity associated with increasing the cut-off point is small …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.